Oral Semaglutide May Drive Solid Growth for NVO Going Forward

On February 22, 2018, Novo Nordisk (NVO) announced the results of its 26-week Phase 3a trial, PIONEER 1, which evaluated the efficacy of oral semaglutide as a treatment option for type 2 diabetes patients in three different daily dosages: 3 mg, 7 mg, and 14 mg. The investigational therapy demonstrated a statistically significant improvement in blood glucose levels compared to the placebo irrespective of the treatment adherence rates of the patients. In cases where patients adhered to the treatment regimen properly, all oral semaglutide dosages demonstrated a robust drop in both the blood glucose levels and body weights of the patients.